Vaccines and compositions against Streptococcus pneumoniae
US-9393294-B2 · Jul 19, 2016 · US
Fused antigen vaccines and compositions against Streptococcus pneumoniae
US9765125B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9765125-B2 |
| Application number | US-201314373179-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 18, 2013 |
| Priority date | Jan 20, 2012 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae that contain fusion proteins. The antigens may be used therapeutically or prophylactically.
First claim
Opening claim text (preview).
We claim: 1. A fusion protein comprising: a first polypeptide comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6 or to the amino acid sequence of SEQ ID NO: 5; and a second polypeptide comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9. 2. The fusion protein of claim 1 , wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 6 or comprises the amino acid sequence of SEQ ID NO: 5, and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 9. 3. The fusion protein of claim 1 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO: 6 or consists of the amino acid sequence of SEQ ID NO: 5. 4. The fusion protein of claim 1 , wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO: 9. 5. The fusion protein of claim 1 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 49. 6. The fusion protein of claim 1 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO: 49. 7. The fusion protein of claim 1 , further comprising a third polypeptide comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 1. 8. The fusion protein of claim 7 , wherein the third polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or comprises the amino acid sequence of SEQ ID NO: 1. 9. The fusion protein of claim 7 , wherein the third polypeptide consists of the amino acid sequence of SEQ ID NO: 2 or consists of the amino acid sequence of SEQ ID NO: 1. 10. The fusion protein of claim 7 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:53. 11. The fusion protein of claim 7 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO:53. 12. The fusion protein of claim 7 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 52. 13. The fusion protein of claim 7 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO: 52. 14. The fusion protein of claim 1 , wherein the fusion protein is lipidated. 15. An immunogenic composition comprising a pharmaceutically acceptable carrier and the fusion protein of claim 1 . 16. The immunogenic composition of claim 15 , further comprising an adjuvant. 17. The immunogenic composition of claim 15 , wherein the immunogenic composition comprises 1-1000 μg of the fusion protein. 18. The fusion protein of claim 1 , wherein the fusion protein comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 49. 19. The fusion protein of claim 7 , wherein the fusion protein comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 53. 20. The fusion protein of claim 7 , wherein the fusion protein comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 52.
Assignees
Inventors
Classifications
- A61K39/092Primary
Streptococcus · CPC title
- C07K14/3156Primary
from Streptococcus pneumoniae (Pneumococcus) (Streptokinase C07K14/3153) · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Fusion polypeptide · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9765125B2 cover?
- Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae that contain fusion proteins. The antigens may be used therapeutically or prophylactically.
- Who is the assignee on this patent?
- Genocea Biosciences Inc, Children'S Medical Center Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K39/092. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).